Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

Also called NCT05196347

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 180 participants (enrolled count) (from the registry)
Sponsor
Kaohsiung Medical University (from the registry)
Registry
  • NCT NCT05196347
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05196347. Randomized; no masking; primary purpose treatment. Start 2022-05-27 (actual); primary completion 2024-08-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease
Acronym
DAPA-advKD
Condition
Chronic Kidney Diseases
Intervention (Drug)
Dapagliflozin
Lead sponsor
Kaohsiung Medical University (class: other)

Record details

Record id
cardio:ct-nct05196347
Content hash
d2498248c8735ba15cc92ec1ed32a3d0c73e6813758a05fb1f29b9802be16469